AVTX - Avalo Therapeutics, Inc.
IEX Last Trade
9.05
0.050 0.552%
Share volume: 18,364
Last Updated: Thu 26 Dec 2024 08:28:42 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$9.00
0.05
0.56%
Fundamental analysis
31%
Profitability
35%
Dept financing
24%
Liquidity
27%
Performance
30%
Performance
5 Days
-3.08%
1 Month
-11.81%
3 Months
-5.78%
6 Months
-32.44%
1 Year
-29.41%
2 Year
-99.27%
Key data
Stock price
$9.05
DAY RANGE
$8.23 - $9.00
52 WEEK RANGE
$4.25 - $22.47
52 WEEK CHANGE
-$25.54
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Garry A. Neil
Region: US
Website: avalotx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: avalotx.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Avalo Therapeutics, Inc. discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease and systemic juvenile idiopathic arthritis.
Recent news